Lead Software Technologist I - UI
About the job
- A Bachelor's or Master's degree in Computer Science, Software Engineering, Information Technology, or equivalent.
- At least 15 years of hands-on experience in front-end or user-interface-heavy application development for embedded or regulated systems, with strong embedded Linux exposure.
- Deep expertise in modern C++, including C++11, C++14, C++17, and C++20, templates, the Standard Template Library, and design patterns.
- Deep expertise in TypeScript, JavaScript, CSS, user-interface architecture, design systems, and performance-critical rendering for embedded or device-hosted applications.
- Strong command of object-oriented programming, memory management, multithreading, and performance optimization.
- Experience with debugging, profiling, and developer-level testing, including unit, component, and behavior-driven development testing with GoogleTest or Catch2.
- Proven hands-on experience using artificial intelligence agent technology as a development companion.
- Proven experience designing and implementing medical or safety-critical applications.
- Experience with technical documentation, code reviews, and compliance with medical software development processes such as IEC 62304.
- Experience developing on embedded Linux, including Yocto or OpenEmbedded.
- Understanding of cybersecurity and data privacy requirements for medical devices.
- Familiarity with Linux-based operating-system stacks tailored for medical devices, including secure boot, sandboxing, and compliance with regulatory standards.
- Proficiency in GitHub, continuous integration and continuous delivery pipelines, and Agile or Scaled Agile Framework methodologies.
- Understanding of patient monitoring systems, medical device safety, and healthcare regulatory requirements.
- Ability to collaborate with clinicians, product managers, and global teams to ensure solutions meet clinical and business needs.
- Ability to influence technical strategy and foster an innovation culture.
- Lead development of intuitive clinical user-interface applications used by clinicians in high-acuity environments.
- Collaborate with user-experience teams and clinicians to ensure applications meet usability and safety requirements.
- Provide technical leadership across modern user-interface technologies and supporting C++ layers for embedded devices.
- Lead and mentor platform development teams on software architecture, design patterns, and embedded-systems best practices through daily hands-on collaboration.
- Lead and mentor application development teams on application services for physiological data visualization and clinical decision-support features.
- Establish and enforce quality standards, development methodologies, and coding practices that drive continuous improvement in software reliability and performance.
- Conduct rigorous code reviews and provide constructive technical feedback to ensure adherence to medical-device software standards and FDA regulations.
- Optimize application performance by identifying and resolving bottlenecks in resource-constrained embedded Linux environments.
- Drive adoption of artificial-intelligence-enabled development tools and demonstrate measurable productivity improvements across the team.
- Collaborate with cross-functional teams, including Product Management, Quality Assurance, Regulatory, and other engineering leads, to define and deliver features.
- Support software lifecycle management activities, including sustaining engineering, defect resolution, and platform evolution.
- Build a culture of technical excellence, innovation, and continuous learning within the Bangalore development organization.
- Represent the technical voice of the team in architectural decisions and strategic technical discussions.
- Hands-on experience with medical communication protocols such as Health Level Seven, Fast Healthcare Interoperability Resources, IEEE 11073 Service-oriented Device Connectivity, and Digital Imaging and Communications in Medicine.
- Experience in healthcare or monitoring-systems domains.
About the company
Philips Respironics designs sleep and respiratory care devices, including CPAP and BiPAP machines, ventilators, and oxygen concentrators, plus related systems. These devices deliver regulated air pressure, support or assist breathing, and provide concentrated oxygen, often paired with software and data tools for monitoring. The division differentiates itself through its long history within Philips and its integrated ecosystem that connects devices with analytics and clinical support across hospital, clinic, and home settings. Its goal is to improve quality of life and clinical outcomes for people with sleep and respiratory conditions by offering reliable devices, patient support, and data-driven care.
Company Size
N/A
Company Stage
Acquired
Total Funding
$164.7M
Headquarters
Murrysville, Pennsylvania
Founded
1891
Simplify's Take
What believers are saying
- More than 99% of registered CPAP and BiPAP recalls were remediated globally by December 2025.
- Philips reported Q1 2026 connected care growth and reiterated full-year guidance in May.
- Respironics-related charges fell to EUR 209 million in 2025 after major settlements finalized.
What critics are saying
- FDA consent decree still bars new U.S. CPAP and BiPAP sales in 2026.
- Repeated FDA noncompliance can keep Philips Respironics locked out of the U.S. market indefinitely.
- The 2021 recall remains active; ventilator remediation and lawsuits keep liability and scrutiny alive.
What makes Philips unique
- Philips Respironics services recalled U.S. devices and sells parts under the 2024 consent decree.
- Outside the U.S., Philips Respironics still sells sleep and respiratory devices in 2026.
- Its 15-million-device installed base gives it unmatched service reach and replacement leverage.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Health Savings Account/Flexible Spending Account
Company News
The global remote patient monitoring market is expected to grow from $67.3 billion in 2026 to $117.9 billion by 2033, registering a CAGR of 8.3%. Growth is driven by rising chronic disease prevalence, expanding telehealth services and increasing demand for home-based healthcare solutions. Devices and hardware account for nearly 38% of market share, led by connected blood pressure monitors, glucometers and wearable health trackers. North America holds approximately 41% of the global market, supported by strong digital healthcare infrastructure and favourable reimbursement policies. Asia Pacific is emerging as the fastest-growing region, driven by healthcare digitisation, telemedicine expansion and rising smartphone penetration. Leading players include Philips Healthcare, Medtronic, GE HealthCare and Abbott Laboratories, focusing on AI integration and cloud connectivity to enhance remote care delivery.
<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US, subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024. The company’s previously announced 2023-2025 financial outlook remains unchanged, already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more
Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.
In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.
February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.